Combination therapy improves progression-free survival in dMMR/MSI-H metastatic colorectal cancer
Patients with deficient DNA mismatch repair (dMMR) or microsatellite instability-high (MSI-H) metastatic colorectal cancer experienced a 58% reduction in the risk of disease progression or death when treated with atezolizumab…